"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 4 | 0 | 4 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 0 | 5 |
| 2005 | 3 | 1 | 4 |
| 2006 | 3 | 0 | 3 |
| 2007 | 4 | 1 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Redirecting thromboxane A2 and prostacyclin biosyntheses from thrombotic to antithrombotic property by an Enzymelink. Future Med Chem. 2021 05; 13(9):765-768.
-
Intensive care management of right ventricular failure and pulmonary hypertension crises. Pediatr Pulmonol. 2021 03; 56(3):636-648.
-
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. Pediatr Pulmonol. 2021 03; 56(3):593-613.
-
The Protective Effects of Up-Regulating Prostacyclin Biosynthesis on Neuron Survival in Hippocampus. J Neuroimmune Pharmacol. 2020 06; 15(2):292-308.
-
A novel single-chain enzyme complex with chain reaction properties rapidly producing thromboxane A2 and exhibiting powerful anti-bleeding functions. J Cell Mol Med. 2019 12; 23(12):8343-8354.
-
Value of perioperative inhaled epoprostenol with low tidal volume ventilation for complex endocarditis surgery. J Card Surg. 2019 Aug; 34(8):676-683.
-
Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454.
-
Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide. J Perinatol. 2018 09; 38(9):1212-1219.
-
How can we address the controversies surrounding the use of NSAIDS in neurodegeneration? Future Med Chem. 2016 07; 8(11):1153-5.
-
Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia. Nat Commun. 2016 Apr 15; 7:11276.